Thursday, June 19, 2014

Newer Biologics at the EULAR 2014 Meeting in Paris

I've listed the newer biologics. Already I've marked some red as there haven't been new studies for a long time or an old study had been presented. This traffic light rating is subjective, but I think it may be helpful. None could be marked green as none is near approval as a drug.

Anti-IL-17 MAB
Brodalumab is doing fine, but the phase 3 study needs further recruiting. Ixekizumab seems to be abandoned as nothing has been published at the EULAR 2014 Meeting and usually the companies see that they publish a minor study. Secukinumab (anti-IL-17a MAB) showed data of a phase 3 study.

Anti-IL-6 MAB
Clazakizumab showed a phase 2b study including radiographic data; I think that's promising. Olokizumab seems to be abandoned as nothing has been published at the EULAR 2014 Meeting. Sarilumab (anti-IL-6 Receptor Alpha MAB met clinical, radiographic, and functional endpoints in a phase 3 study.

Anti-CD-6 MAB
Itolizumab showed results, that "provide strong preliminary evidence for the safety and efficacy".

Fibronectin-A-chain connected to IL-10
There's only one MAB and it's called dekavil. The study group presented 7 patients at the EULAR 2013 Meeting, 14 patients at the ACR 2013 Meeting, and now 20 patients. The patients were recruited in four different centers. I don't see the future of this approach as favourable as the authors.

Anti-GM-CSFR-Alpha MAB
Mavrilimumab has been presented in two studies, but no phase 3 study, but I guess that recruiting is a problem.

Anti-complement-factor-5a-receptor MAB
NNC0151-0000 has been stopped because of side effects. NNC0215-0384 is in phase 1.

Anti-B Cell Activating Factor MAB
Tabalumab has been presented with a phase 3 study (N=456) in two abstracts, but "demonstrated no clinical efficacy despite evidence of biologic activity, suggesting that targeting BAFF may not be a viable therapeutic approach to treating pts with RA."

Quite a lot of dead ends! But some interesting developments to get drugs with new modes of action as some of the existing options might not work due to class effects.


No comments:

Post a Comment